Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
OREX Hot Sheet
Revenue Growth %: -53.2%Financial Fact:
License revenue: 0
Today's EPS Names:
TNP, MENT, More
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reports Q3 loss of $0.33, 3 cents better than the analyst estimate of ($0.36).
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
